ArticlePediatric pulmonology2026
Caregiver Mental Health and Its Relation to Child and Adolescent Mental and Behavioral Health in the Era of Highly Effective Modulator Therapy for Cystic Fibrosis.
Article in Pediatric pulmonology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundElexacaftor/tezacaftor/ivacaftor (ETI) has led to marked improvements in physical health outcomes but inconsistent findings regarding changes in mental and behavioral health outcomes for youth with cystic fibrosis (YWCF) and their caregivers.
objectivesTo describe the prevalence of mental/behavioral health symptoms in YWCF taking ETI and their caregivers, and to examine the association between caregiver and youth mental/behavioral health symptoms.
methodIn this cross-sectional study, 118 YWCF (ages 7-17) and their caregivers from 11 U.S. CF centers participated. Standardized self-report and parent-proxy screening measures assessed symptoms of depression, anxiety, attention deficit hyperactivity disorder (ADHD), externalizing behaviors, and sleep disturbance. Descriptive statistics summarized prevalence and Spearman Rho correlations were used to analyze associations.
resultsThe point prevalence of mild or moderate/severe depressive symptoms was 23.3% (95% CI: 16, 31) for caregivers, 27.1% (95% CI: 15, 40) for children (ages 7-12), and 28.6% (95% CI: 18, 39) for adolescents (ages 13-17). The point prevalence for mild or moderate/severe anxiety symptoms was 23.1% (95% CI: 15, 31) for caregivers, 31.3% (95% CI: 18, 44) for children, and 18.8% (95% CI: 10, 28) for adolescents. Some YWCF exceeded clinical cutoffs for sleep disturbance (29.8-35.0%), attention (11.4-14.9%), and externalizing behavior (5.7-8.5%). Caregiver mental health scores and child mental/behavioral health scores were positively correlated (ρ = 0.20 - 0.52, p's < 0.05).
conclusionsThough most YWCF and caregivers report few to no mental/behavioral health symptoms, many still report clinically elevated levels, suggesting the continued need to screen for mental health concerns in the evolving context of highly effective CF treatment. Our results also indicate that screening should expand to areas beyond anxiety and depression, such as sleep, as well as the possible need for developing family-based mental health care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.